Respiratory

Pharmacist management of chronic conditions can lead to improved patient outcomes.

Three RSV vaccines are currently FDA approved for use in adults aged 60 or older.

On June 26, 2024, the FDA approved ensifentrine (Ohtuvayre) for the treatment of COPD.

Researchers addressed the prevalence of RSV and its associations with immunization, infection, and hospitalization amongst older adults.

Recent research on vitamin D supplementation and respiratory tract infections can help guide pharmacists in counseling patients.

GSK’s respiratory syncytial virus vaccine continued to provide adults aged 60 years and older with clinically meaningful protection.

This year’s annual meeting of the American College of Chest Physicians featured more than 300 educational sessions, insights from over 600 faculty members, and 29.5 hours of CE credits.

Two posters presented at the annual meeting of the American College of Chest Physicians, CHEST 2024, offered insights into the accurate diagnosis and appropriate treatment of ACOS.

Research Presented at CHEST 2024 reported on how mepolizumab can improve asthma control, and reduce exacerbations of concurrent asthma and COPD.

The Healgen Rapid Check COVID-19/Flu A&B Antigen Test is the first at-home test to be granted marketing authorization using a traditional premarket review pathway.

Research presented at CHEST 2024 examined the effect of steroid choice on individuals who have a dual diagnosis of heart failure and COPD.

Research being presented at CHEST 2024 analyzed morbidity and outcomes of children infected with influenza, COVID-19 or both.

The company will be presenting the full BATURA study data as a late-breaker oral presentation at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting.

This year’s meeting will take place from October 6 to 9 in Boston, Massachusetts.

Investigators suggested that the future cost-effectiveness of respiratory syncytial virus (RSV) vaccination could be improved through lower vaccine prices and longer-lasting protection.

The National Foundation for Infectious Diseases released a survey regarding the feelings of US adults toward influenza, COVID-19, RSV, and pneumococcal disease.

Dupixent is a fully human monoclonal antibody that inhibits the signaling of the IL4 and IL13 pathways.

Initiatives such as media campaigns and legislative rulings by the agencies have likely contributed to the decline.

A co-administration option for both vaccinations can increase the likelihood of older adults completing the vaccination series and improve health outcomes for the patient population.

Researchers analyzed the outcomes of positive airway pressure therapy for Medicare beneficiaries with obstructive sleep apnea.

Data from the SWIFT-1 and SWIFT-2 studies were presented by GSK at the European Respiratory Society International Conference.

The government said the tests will “detect current COVID-19 variants and can be used through the end of the year.”

Novavax is still awaiting FDA authorization for their protein-based COVID-19 vaccine.

Final approval of the therapy may occur after expiration of the 3-year regulatory exclusivity for Tyvaso DPI on May 23, 2025.

Ragweed season begins in late August and can run through early November.

The composition of the latest flu vaccine has changed. Here’s what pharmacists need to know.

The American College of Allergy, Asthma, and Immunology (ACAAI) recently released its 5 tips to help children and their parents stay educated on asthma peak month.

MK-1654 (clesrovimab) met its primary efficacy endpoint of incidence of patients with RSV-associated medically attended lower respiratory infections (MALRI) through Day 150.

Current recommendations suggest women receive the RSV vaccine between 32 and 36 weeks' gestational age.

The updates follow the Advisory Committee for Immunization Practice meeting held June 26 to 28, 2024.